Patents
Literature
57 results about "Treatment-resistant depression" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Treatment-resistant depression (TRD) is a term used in clinical psychiatry to describe a condition that affects people with major depressive disorder (MDD) who do not respond adequately to a course of appropriate antidepressant medication within a certain time. Typical definitions of TRD vary, and they do not include a resistance to psychological therapies. Inadequate response has traditionally been defined as no clinical response whatsoever (e.g. no improvement in depressive symptoms). However, many clinicians consider a response inadequate if the person does not achieve full remission of symptoms. People with treatment-resistant depression who do not adequately respond to antidepressant treatment are sometimes referred to as pseudoresistant. Some factors that contribute to inadequate treatment are: early discontinuation of treatment, insufficient dosage of medication, patient noncompliance, misdiagnosis, and concurrent psychiatric disorders. Cases of treatment-resistant depression may also be referred to by which medications people with TRD are resistant to (e.g.: SSRI-resistant). In TRD adding further treatments such as psychotherapy, lithium, or aripiprazole is weakly supported as of 2019.
Bupropion dosage forms with reduced food and alcohol dosing effects
This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g., major depressive disorder, including treatment-resistant depression, agitation associated with Alzheimer's disease (or agitation associated with dementia of the Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety disorder), neuropathic pain, or peripheral diabetic neuropathic pain) comprising, administering a dosage form described herein to a human being in need thereof.
Owner:ANTECIP BIOVENTURES II LLC
Bupropion dosage forms with reduced food and alcohol dosing effects
This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g., major depressive disorder, including treatment-resistant depression, agitation associated with Alzheimer's disease (or agitation associated with dementia of the Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety disorder), neuropathic pain, or peripheral diabetic neuropathic pain) comprising, administering a dosage form described herein to a human being in need thereof.
Owner:ANTECIP BIOVENTURES II LLC
Treatment of treatment resistant depression with psilocybin
The disclosure provides methods for treating treatment-resistant depression a subject in need thereof comprising administering to the subject two or more doses of psilocybin. The methods described herein may be used to treat subjects both responsive and unresponsive to a first dose of psilocybin
Owner:COMPASS PATHFINDER LTD
Bupropion dosage forms with reduced food and alcohol dosing effects
ActiveUS20250268891A1Nervous disorderHydroxy compound active ingredientsIngested foodTreatment-resistant depression
This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g., major depressive disorder, including treatment-resistant depression, agitation associated with Alzheimer's disease (or agitation associated with dementia of the Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety disorder), neuropathic pain, or peripheral diabetic neuropathic pain) comprising, administering a dosage form described herein to a human being in need thereof.
Owner:ANTECIP BIOVENTURES II LLC
Methods for treating treatment resistant depression
The present disclosure provides methods and dosing regimens for the treatment of depression (e.g., treatment resistant depression) with a mucoadhesive composition comprising N, N-dimethyltryptamine (DMT) or a pharmaceutically acceptable salt thereof.
Owner:ATAI THERAPEUTICS INC
Evaluation system based on intracranial magnetic stimulation treatment effect of intracranial depression
The invention provides an evaluation system based on a transcranial magnetic stimulation treatment effect of refractory depression, and belongs to the field of transcranial magnetic stimulation treatment evaluation. The problem that the objectivity and interpretability of an evaluation result are insufficient due to the fact that multi-modal data are not effectively integrated in the prior art is solved. The system comprises a neural navigation module which is used for determining an individualized transcranial magnetic stimulation target spot through a resting state functional magnetic resonance imaging technology and a remote isolation effect principle; the periodic treatment module is used for carrying out cranial magnetic stimulation frequency setting by adopting an alternate theta burst stimulation scheme; the data acquisition and processing module is used for acquiring multi-modal data before and after treatment and performing feature extraction; and the treatment evaluation module is used for establishing a multi-modal fusion curative effect prediction model through a support vector machine, and the model is used for evaluating the treatment effect and predicting the symptom relieving degree after being trained by a training data set. The method is mainly used in data evaluation field.
Owner:QIQIHAR MEDICAL UNIVERSITY
Tryptamine prodrugs
ActiveJP2025143280AOrganic active ingredientsPowder deliveryPost-pregnancy depressionGeneralized anxiety
To provide a compound useful for the treatment of mental disorders, such as a depressive condition including unipolar and bipolar depressive conditions, for example, but not limited to, depression, depression from generalized anxiety, major depression, treatment resistant depression, and postpartum depression.SOLUTION: The present invention provides a tryptamine prodrug compound represented by the following formula.SELECTED DRAWING: Figure 1
Owner:REUNION NEUROSCIENCE INC
Predicting response to nummulin therapy for refractory depression
Methods for predicting response to administration therapy are provided. One or more records of a session associated with administration of a therapy may be transcribed into one or more transcripts. The transcript may be parsed into an utterance. An utterance emotion for a single utterance may be determined, and a response to the administration therapy may be predicted based at least in part on the utterance emotion.
Owner:指南针探路者有限公司
Induction regime for the administration of 2-(2-chlorphenyl)-2-(methylamino) cyclohexan-1-one
PCT designated stage expiredWO2025099182A1Organic active ingredientsNervous disorderKetamineMedicinal chemistry
The present invention relates to administration regimes of 2-(2-Chlorphenyl)-2- (methylamino) cyclohexan-1-one, also known as ketamine, or derivatives thereof, for the use in treating depression, in particular treatment resistant depression.
Owner:HMNC HLDG GMBH
Uses of JAK Inhibitors in the Management of Inflammation-Associated Depression and Central Nervous System (CNS) Pathologies
This disclosure relates to methods of treating, preventing, or reversing inflammation-associated central nervous system (CNS) disorders or conditions comprising administering an effective amount of a Janus kinases (JAK) inhibitor such as baricitinib to a patient in need thereof. In certain embodiments, the CNS associated inflammatory disorder is depression, treatment resistant depression, fatigue, or cognitive dysfunction.
Owner:EMORY UNIVERSITY +1
Automated diagnosis and treatment of mood and psychotic disorders using membrane protein clustering
Blood-based biomarkers involving evaluation of membrane protein clustering (MPC) on peripherally circulating lymphocytes can identify individuals experiencing depression, schizophrenia, or bipolar disorder, while differentiating those that will respond to treatment from those that will not respond to treatment within the depressed populations. These markers can help diagnose and treat depression, schizophrenia, or bipolar disorder. Further, this diagnostic tool can identify individuals with treatment-resistant depression earlier. The disclosed automated method improves the throughput of blood-based biomarkers and can be standardized across multiple sites of blood collection / analysis. The automated approach performs similarly to human scorers for each method of blood smear collection in accurately obtaining cluster size means for each sample.
Owner:UVIC INDUSTRY PARTNERSHIPS INC
Methods of treating treatment resistant depression
PCT designated stageWO2026030301A1Nervous disorderPharmaceutical delivery mechanismDosing regimenRegimen
The present disclosure provides methods and dosing regimens for the treatment of depression (e.g., treatment resistant depression) with a mucoadhesive composition comprising N, N-dimethyltryptamine (DMT) or a pharmaceutically acceptable salt thereof.
Owner:ATAI THERAPEUTICS INC
R-ketamine liquid preparation and use thereof
Disclosed in the present application is an R-ketamine liquid preparation. The R-ketamine liquid preparation is an aqueous solution preparation, and comprises R-ketamine or a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable amphiphilic excipient, and water. The liquid preparation has a pH value of 2.5-5.7. The liquid preparation of the present application is administrated through oral mucosa, and features fast absorption, high bioavailability, simple administration, and good compliance. The preparation of the present application can be used for preventing, relieving, or treating major depression, unipolar depression, refractory depression, intractable depression, agitated depression, and bipolar depression.
Owner:YICHANG HUMANWELL PHARMA CO LTD
Subcutaneous formulations comprising psilocybin derivatives
PCT designated stageWO2026017869A1Organic active ingredientsNervous disorderSubcutaneous injectionNeuropsychiatric disease
The present disclosure provides stable liquid formulations comprising Compound (1), or a pharmaceutically acceptable salt of Compound (1), and one or more pharmaceutically acceptable excipients. The liquid formulation may comprise a pH buffered aqueous solution, and optionally a pH modifier and / or a tonicity agent. Also provided herein are methods of delivering the formulation via parenteral administration (e.g., subcutaneous injection), and methods of using the formulation in the treatment of neuropsychiatric diseases (e.g., treatment resistant depression).
Owner:COMPASS PATHFINDER LTD
Therapeutic methods using bupropion hydrobromide
PendingUS20250177326A1Organic active ingredientsNervous disorderTherapeutic effectBupropion Hydrobromide
Disclosed are methods of treating a patient having Major Depressive Disorder (MDD) or Treatment Resistant Depression (TRD). The methods include administering to the patient a therapeutically effective amount of bupropion hydrobromide in extended-release form. The methods are more therapeutically effective in treating MDD or TRD than administration of an equivalent plasma dose of bupropion hydrochloride in extended-release form. In addition or alternatively, the therapeutically effective amount of bupropion hydrobromide reduces the incidence of one or more adverse events (anxiety, agitation and / or insomnia), when compared to the administration of the equivalent plasma dose of bupropion hydrochloride in extended-release form.
Owner:PRICE RICHARD LOUIS +1
Antidepressant compound 4-methyl-6-methoxycoumarin
PendingCN121754531ANervous disorderHeterocyclic compound active ingredientsTherapeutic effectSleep wake
The invention relates to an anti-depression compound 4-methyl-6-methoxy coumarin, and belongs to the technical field of biological medicines. Depression is the most common mental disorder in the world and is also a main reason for disability. The development of a novel anti-depression drug which is based on a nerve plasticity mechanism, takes effect quickly, has a lasting curative effect and is high in safety, and particularly has important clinical requirements and technical necessity for an effective treatment means for refractory depression. Traditional Chinese medicine monomers and a per2- / -zebra fish depression model are adopted for anti-depression drug screening, and finally it is found that 10 mM of 4-methyl-6-methoxycoumarin has the anti-depression characteristic and has the positive treatment effect on the exploration behavior, social interaction and sleep-awakening period of per2- / -zebra fish. The method can effectively rescue and reverse depression-like phenotypes observed in a per2- / -zebra fish circadian rhythmic depression model, and can restore the balance of important gene expression.
Owner:SUZHOU UNIV
Construction method of drug-resistant depression animal model
The invention belongs to the technical field of animal model construction, and discloses a construction method of a drug-resistant depression animal model. A Cx43flox / flox mouse is constructed through a CRISPR / Cas9 technology, an AAV virus vector of Cre recombinase encoding a GfaABC1D promoter is further injected into the forehead cortex in a positioned mode, and a model mouse of the forehead cortex with the astrocyte Cx43 being conditionally knocked out is constructed. Through behavioral experiments and inflammatory reaction detection, depression-like behaviors of animals in the model and inflammatory reaction of the forehead cortex are evaluated, and treatment failure of antidepressant drugs on the model is observed. According to the invention, the drug-resistant depression animal model can be stably, simply and repeatedly constructed, and a research basis is provided for research on the pathogenesis of refractory depression and development of antidepressant drugs.
Owner:INST OF MATERIA MEDICA CHINESE ACAD OF MEDICAL SCI
Induction regimen for administering 2-(2-chlorophenyl)-2-(methylamino)cyclohexan-1-one
The present invention relates to a dosing regimen of 2-(2-chlorophenyl)-2-(methylamino)cyclohexan-1-one, also known as ketamine, or a derivative thereof for use in the treatment of depression, in particular treatment resistant depression.
Owner:HMNC HOLDINGS
Maintenance regime for the administration of 2-(2-chlorphenyl)-2-(methylamino) cyclohexan-1-one
PCT designated stage expiredWO2025099181A1Organic active ingredientsNervous disorderPerylene derivativesKetamine
The present invention relates to administration regimes of 2-(2-Chlorphenyl)-2- (methylamino) cyclohexan-1-one, also known as ketamine, or derivatives thereof, for the use in treating depression, in particular treatment resistant depression.
Owner:HMNC HLDG GMBH
Methods of diagnosing and treating mood and psychotic disorders using lymphocyte biomarkers
Blood-based biomarkers involving evaluation of membrane protein clustering (MPC) on peripherally circulating lymphocytes can identify individuals experiencing depression, schizophrenia, or bipolar disorder, while differentiating those that will respond to treatment from those that will not respond to treatment within the depressed populations. These markers can help diagnose and treat depression, schizophrenia, or bipolar disorder. Further, this diagnostic tool can identify individuals with treatment-resistant depression earlier. The disclosed automated method improves the throughput of blood-based biomarkers and can be standardized across multiple sites of blood collection / analysis. The automated approach performs similarly to human scorers for each method of blood smear collection in accurately obtaining cluster size means for each sample.
Owner:UVIC INDUSTRY PARTNERSHIPS INC +3
Methods of diagnosing and treating mood and psychotic disorders using lymphocyte biomarkers
Blood-based biomarkers involving evaluation of membrane protein clustering (MPC) on peripherally circulating lymphocytes can identify individuals experiencing depression, schizophrenia, or bipolar disorder, while differentiating those that will respond to treatment from those that will not respond to treatment within the depressed populations. These markers can help diagnose and treat depression, schizophrenia, or bipolar disorder. Further, this diagnostic tool can identify individuals with treatment-resistant depression earlier. The disclosed automated method improves the throughput of blood-based biomarkers and can be standardized across multiple sites of blood collection / analysis. The automated approach performs similarly to human scorers for each method of blood smear collection in accurately obtaining cluster size means for each sample.
Owner:UVIC INDUSTRY PARTNERSHIPS INC +3
A new combination therapy for treatment-resistant depression in patients with co-morbid metabolic syndrome
PCT designated stageWO2026015878A1Nervous disorderEster active ingredientsDepressed - symptomCombination therapy
The invention provides a composition and method of treating depression by administering to a patient in need of such treatment a combination of pindolol and fenofibrate in a ratio of about 3mg pindolol / 33mg fenofibrate and is useful in augmentation to treatment of depression.
Owner:MINDX THERAPEUTICS INC
Automated diagnosis and treatment of mood and psychotic disorders using membrane protein clustering
Blood-based biomarkers involving evaluation of membrane protein clustering (MPC) on peripherally circulating lymphocytes can identify individuals experiencing depression, schizophrenia, or bipolar disorder, while differentiating those that will respond to treatment from those that will not respond to treatment within the depressed populations. These markers can help diagnose and treat depression, schizophrenia, or bipolar disorder. Further, this diagnostic tool can identify individuals with treatment-resistant depression earlier. The disclosed automated method improves the throughput of blood-based biomarkers and can be standardized across multiple sites of blood collection / analysis. The automated approach performs similarly to human scorers for each method of blood smear collection in accurately obtaining cluster size means for each sample.
Owner:UVIC INDUSTRY PARTNERSHIPS INC
Monoacylglycerol Lipase Modulators
Fused compounds of Formula (I) and Formula (II), pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, bipolar disorder), cancers and eye conditions.Wherein R1, R2, R2a, R3, R3a, R4, and R4a are defined herein.
Owner:JANSSEN PHARMA NV
Treatment for refractory depression with glycyrrhizin
Owner:MURCK HARALD WESTFIELD
Bupropion dosage forms with reduced food and alcohol dosing effects
This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g., major depressive disorder, including treatment-resistant depression, agitation associated with Alzheimer's disease (or agitation associated with dementia of the Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety disorder), neuropathic pain, or peripheral diabetic neuropathic pain) comprising, administering a dosage form described herein to a human being in need thereof.
Owner:ANTECIP BIOVENTURES II LLC
Use of pharmaceutical composition
PCT designated stageWO2026052068A1Organic active ingredientsNervous disorderPharmaceutical drugPharmaceutical Substances
The present disclosure relates to use of a pharmaceutical composition. Specifically, the pharmaceutical composition provided by the present disclosure is used for treating inflammatory depression, wherein the pharmaceutical composition comprises: (i) dextromethorphan or a salt of dextromethorphan and (ii) celecoxib or a salt of celecoxib. The pharmaceutical composition of the present disclosure is directed to inflammatory depression (especially inflammatory treatment-resistant depression and anhedonia depression).
Owner:PRECISION BRAIN SCIENCE BIOTECHNOLOGY (SUZHOU) CO LTD
Pharmaceutical composition and application thereof
The invention relates to a pharmaceutical composition. The pharmaceutical composition comprises two active ingredients: (1) votioxetine or a pharmaceutically acceptable salt thereof; and (2) olanzapine, the weight ratio of the vothioxetine or the pharmaceutically acceptable salt thereof to the olanzapine is (6-50): (3-6), preferably (9-50): 6, and the weight of the two active ingredients is calculated in a free form. The invention further relates to a pharmaceutical preparation prepared from the composition and application of the pharmaceutical composition and the pharmaceutical preparation in prevention and / or treatment of depression and other diseases, and the application comprises the step of applying an effective amount of the pharmaceutical composition or the pharmaceutical preparation to a patient in need. The pharmaceutical composition disclosed by the invention can be used for treating bipolar affective disorder, refractory depression and anxiety and improving cognition, and also has the advantages of small side effect and good patient compliance.
Owner:SEASONS BIOTECHNOLOGY (TAIZHOU) CO LTD
Application of pharmaceutical composition
PendingCN120939027AOrganic active ingredientsNervous disorderPharmaceutical drugPharmaceutical Substances
The present disclosure relates to uses of a pharmaceutical composition. Specifically, the pharmaceutical composition provided by the invention is used for treating inflammatory depression, and the pharmaceutical composition comprises (i) dextromethorphan or a salt of dextromethorphan and (ii) celecoxib or a salt of celecoxib. The pharmaceutical composition disclosed by the invention is used for treating inflammatory depression (especially inflammatory refractory depression and pleasant sensation deficiency type depression).
Owner:PRECISION BRAIN SCIENCE BIOTECHNOLOGY (SUZHOU) CO LTD
Galanin (1-15) and fluoxetine in the treatment of treatment-resistant depression
PCT designated stageWO2026013329A1Organic active ingredientsNervous disorderDepressantDepressed - symptom
Galanin (1-15) and fluoxetine in the treatment of treatment-resistant depression, GAL (1-15) in combination with a seratonin reuptake inhibitor, preferably fluoxetine, for use in the treatment of treatment-resistant depression, and a composition comprising same.
Owner:UNIV DE MALAGA